Flixabi, an infliximab biosimilar candidate referencing Remicade, receives positive CHMP opinion
![](/46/pdcnewsitem/03/98/46/biogen.jpg)
Flixabi to be the second anti-TNF biosimilar commercialized and manufactured by Biogen in the EU.
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the marketing authorization of Flixabi (infliximab). Previously known as SB2, Flixabi is an infliximab biosimilar candidate referencing Remicade, which was developed by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union (EU). If approved by the EC, Flixabi could be prescribed in the same indications as Remicade. This includes treatment of adults with rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Flixabi could also be used in patients 6 to 17 years old with severe, active Crohn’s disease or severely active ulcerative colitis.
The positive CHMP opinion comes shortly after marketing authorization was granted for Benepali (etanercept), a biosimilar referencing Enbrel. Both Flixabi and Benepali are anti-TNF therapies, a treatment class which accounts for the largest prescribed segment of the global biologics market.
“The positive CHMP opinion for Flixabi marks another important milestone for our biosimilars business this year. We are excited to harness this positive momentum as we prepare to bring our second biosimilar treatment to patients in the EU,” said Alpna Seth, Senior Vice President and Global Head of the Biosimilars Business Unit at Biogen. “Biogen is building upon its deep expertise in manufacturing and commercializing biologics for immunological conditions by bringing forth these important therapies. Biosimilars will increase choice and access for patients in the EU, while providing potential cost savings to healthcare systems.”
The CHMP’s positive opinion was based on a robust preclinical and clinical data package submitted to the European Medicines Agency by Samsung Bioepis. Data in the preclinical submission established similarity and comparability between Flixabi and its reference product, Remicade. The clinical submission included confirmatory data from head-to-head Phase I and Phase III clinical trials comparing Flixabi to the reference product.
The 54-week, double-blind, Phase III study was conducted in patients with moderate to severe RA despite methotrexate therapy. The primary end point was the American College of Rheumatology 20% (ACR20) response at week 30 in the per-protocol set (PPS). ACR20 evaluates effectiveness of RA treatments by measuring improvement in physical and clinical measures, including tender and swollen joint counts, a key symptom of RA. The primary end point for the study was met, with data showing patients taking Fabi had an equivalent ACR20 response and a comparable safety profile to those taking Remicade.
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance